Cannabis Science Releases Positive Laboratory Results From Both The EU Certified As Well As Its Own Unique Cannabis Strains Grown In Its Spain Operations
ANALYTICAL RESULTS INDICATE SUCCESSFUL MOVE TO THE NEXT STAGE OF PROTOCOLS FOR PRE-CLINICAL DRUG DEVELOPMENT
COLORADO SPRINGS, Colo., Oct. 28, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is very pleased with the laboratory analytical reports it recently received. The testing of the cannabis harvested using EU certified as well as its own unique strains produced end results indicating that whole extracts to be produced will contain upward of 20% CBD and less than 10% THC. Furthermore, other unique identifiers are present that require multiple authentications based on their significant nature.
These numbers are significant based on usage information and expected treatment regimes for many of the Company targeted ailments. The Company continues investigating both its unique cannabinoid strains as well as promising strains from around the world for multiple pre-clinical drug development programs targeting Cancer, Neurological Disorders, and a few other targeted critical ailments to be announced.
Mr. Mario S. Lap, Director and President of European Operations, stated, “The current progress is very exciting based on the numbers and the number of harvests we have processed thus far. This data received is critical in the initial stages of our drug development programs. We are now focused on the successful scalability and portability towards whole extracts targeting GMP production requirements for our pre-clinical programs. This includes intensive research and conducting laboratory tests of the active constituents contained in the cannabis plant. We believe the potential medicinal applications using cannabis have shown positive treatments results for each of our targeted ailments.”
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Mr. Mario S. Lap, Director, President of European Operations
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org